NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Dr. Reddy's Laboratories Limited (RDY) Stock Analysis

Dr. Reddy's Laboratories Limited (RDY) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

RDY

$11.97

−$0.06 (−0.50%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RDY with… →

RDY Key Statistics

As of Sep 4, 2026
Trading
Open
$12.01
Previous Close
$12.03
Day's Range
11.91–12.06
52-Week Range
11.36–15.67
Volume
2.34M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.24
Valuation
Market Cap
$9.97B
P/E Ratio
28.50
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
18.22
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.59
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.03
EPS (ttm)Profit attributable to each share over the last twelve months.
0.42
Financials (FY)
Revenue (FY)
$335.93B+3.19%
Net Income (FY)
$42.85B−24.22%
Profit marginThe share of revenue left as profit after all costs and taxes.
10.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
832.99M
1-Year Return
−14.81%
Dividend and dates
Dividend
$0.08+0.69%
Ex-Dividend Date
July 9, 2026
Earnings Date
October 22, 2026estimated
Avg Volume
2.73M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RDY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.14%
2025−10.53%
2024+14.13%
2023+36.48%
2022−19.74%
2021−7.34%
2020+76.80%
2019+8.45%
2018+1.26%
2017−16.43%
2016 (partial year)−1.07%

As of September 4, 2026.

RDY Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$335.93B$42.85B12.8%
2024$325.54B$56.54B17.4%
2023$279.16B$55.68B19.9%
2022$245.88B$45.07B18.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$335.93B$177.26B$50.12B$42.85B12.8%
2024$325.54B$190.43B$72.01B$56.54B17.4%
2023$279.16B$163.61B$65.31B$55.68B19.9%
2022$245.88B$139.34B$59.05B$45.07B18.3%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

RDY Dividend History

$0.09−5.0% vs 2024

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2026*$0.081—
2025$0.091−5.0%
2024$0.101−50.9%
2023$0.202+27.6%
YearDividends per sharePaymentsChange
2026 (partial year)$0.081—
2025$0.091−5.0%
2024$0.101−50.9%
2023$0.202+27.6%
2022$0.152+12.8%
2021$0.142+105.5%
2020$0.071+15.0%
2019$0.061−3.4%
2018$0.061−4.2%
2017$0.061—

Most recent payment: $0.08 per share, ex-dividend July 24, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

RDY Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricRDYDrug Manufacturers - Specialty & Generic medianvs median
P/E28.5019.2748% above
P/S ratio0.032.300.0x the median
Profit margin10.00%−3.14%13.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Dr. Reddy's Laboratories Limited (RDY) is capitalised at $9.97B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 27,527 employees.

Over the past 52 weeks the price has ranged from $11.36 to $15.67. RDY last closed at $11.97 on September 4, 2026. That is −$0.06 (−0.50%) against the previous close. The latest close sits 5.37% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $335.93B. Against the prior fiscal year total of $325.54B, that is a change of +3.19%. Net income for the same year was $42.85B. That is −24.22% against the prior fiscal year. Profit margin runs at 10%. That is 13.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 0.42.

Across the 4 fiscal years on file, revenue moves from $245.88B in 2022 to $335.93B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 28.5. That is 47.94% above the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 18.22. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.59. Measured against sales, the shares trade at 0.03 times revenue. On price-to-sales that is 0 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.24. Daily returns over the trailing 10 years annualize to a volatility of 26.44%. Over the trailing twelve months the price has returned −14.81%. Measured over 10 years, that is +3.37% a year compounded.

Growth & Income

Shareholders receive a dividend, yielding 0.69% on the latest price. That is 1.4 percentage points below the Drug Manufacturers - Specialty & Generic median yield of 2.06%. The indicated annual rate is $0.08 a share. The ex-dividend date on file is July 9, 2026. Dividends are recorded for 10 calendar years; 2026 shows 1 payments totalling $0.08 a share. The year before, 2025, totalled $0.09 a share.

Across the complete calendar years on file, 2020 returned +76.80% and 2022 returned −19.74%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is −14.14%.

Peer Comparison

Dr. Reddy's Laboratories Limited (RDY) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Dr. Reddy's Laboratories Limited RDY $9.97B 28.5
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Dr. Reddy's Laboratories Limited trades at a P/E of 28.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Visit website →